MRNA’s key COVID-19 developments so far
- US government is willing to fund mRNA-173 through every trial until regulatory approval.
- Biomedical Advanced Research and Development Authority (BARDA) is ready to give Moderna (NASDAQ: MRNA) $483 million to expedite mRNA-173 through clinical development.
- Lonza Group, via its agreement with Moderna, is manufacturing mRNA-173 at their US and Switzerland operations.